Literature DB >> 18997057

Cytotoxicity of sigma-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the sigma-2 subpopulation.

Anna A Rybczynska1, Rudi A Dierckx, Kiichi Ishiwata, Philip H Elsinga, Aren van Waarde.   

Abstract

UNLABELLED: Tumor cells can be selectively killed by application of sigma-ligands; high concentrations (20-100 muM) are often required, however, because either diffusion barriers must be passed to reach intracellular sites or the entire sigma-receptor population should be occupied to induce cell death. We measured receptor occupancies associated with the cytotoxic effect and dose-dependent changes of cellular metabolism in a tumor cell line.
METHODS: C6 cells (rat glioma) were grown in monolayers and exposed to (+)-pentazocine (sigma-1 agonist), AC915 (sigma-1 antagonist), rimcazole (sigma-1/sigma-2 antagonist), or haloperidol (sigma-1/sigma-2 antagonist). Occupancy of sigma-receptors by the test drugs was measured by studying the competition of the test drugs with cellular binding of the ligand (11)C-SA4503. Metabolic changes were quantified by measuring cellular uptake of (18)F-FDG, (18)F-FLT, (11)C-choline, or (11)C-methionine. Cytotoxicity was assessed by cellular morphology observation and cell counting after 24 h.
RESULTS: IC(50) values (drug concentrations resulting in 50% occupancy of the available binding sites) of the test drugs for inhibition of cellular (11)C-SA4503 binding were 6.5, 7.4, 0.36, and 0.27 muM for (+)-pentazocine, AC915, rimcazole, and haloperidol, respectively. EC(50) values (dose required for a 50% reduction of cell number after 24 h) were 710, 819, 31, and 58 muM, for pentazocine, AC915, rimcazole, and haloperidol, respectively. Cytotoxic doses of sigma-ligands were generally associated with increased uptake of (18)F-FDG, decreased uptake of (18)F-FLT and (11)C-choline, and little change in (11)C-methionine uptake per viable cell.
CONCLUSION: IC(50) values of the test drugs reflect their in vitro affinities to sigma-2 rather than to sigma-1 receptors. Because cytotoxicity occurred at concentrations 2 orders of magnitude higher than IC(50) values for inhibition of cellular (11)C-SA4503 binding, high (99%) occupancy of sigma-2 receptors is associated with loss of cell viability. (18)F-FLT, (11)C-choline, and (18)F-FDG responded most strongly to drug treatment and showed changes corresponding to the cytotoxicity of the test compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997057     DOI: 10.2967/jnumed.108.053876

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

2.  Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity.

Authors:  Satishkumar Gadhiya; Sudharshan Madapa; Thomas Kurtzman; Ian L Alberts; Steven Ramsey; Nagavara-Kishore Pillarsetty; Teja Kalidindi; Wayne W Harding
Journal:  Bioorg Med Chem       Date:  2016-03-21       Impact factor: 3.641

3.  Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands.

Authors:  Suping Bai; Shihong Li; Jinbin Xu; Xin Peng; Kiran Sai; Wenhua Chu; Zhude Tu; Chenbo Zeng; Robert H Mach
Journal:  J Med Chem       Date:  2014-05-12       Impact factor: 7.446

4.  Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.

Authors:  Marco de Bruyn; Anna A Rybczynska; Yunwei Wei; Michael Schwenkert; Georg H Fey; Rudi A J O Dierckx; Aren van Waarde; Wijnand Helfrich; Edwin Bremer
Journal:  Mol Cancer       Date:  2010-11-23       Impact factor: 27.401

5.  The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.

Authors:  John R Hornick; Jinbin Xu; Suwanna Vangveravong; Zhude Tu; Jonathan B Mitchem; Dirk Spitzer; Peter Goedegebuure; Robert H Mach; William G Hawkins
Journal:  Mol Cancer       Date:  2010-11-22       Impact factor: 27.401

Review 6.  Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes.

Authors:  Halley M Oyer; Christina M Sanders; Felix J Kim
Journal:  Front Pharmacol       Date:  2019-10-21       Impact factor: 5.810

Review 7.  Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).

Authors:  Sadek Malas; Micaela Harrasser; Katie E Lacy; Sophia N Karagiannis
Journal:  Oncol Rep       Date:  2014-06-20       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.